Vorasidenib

Vorasidenib is an experimental anti-cancer medication for the treatment of low-grade glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer. In a phase-III-trial, it was shown to prolong progression-free survival in patients with IDH1- or IDH2-mutant low-grade glioma.